Cardiol Therapeutics Inc. CRDL
Cardiol Therapeutics Inc. (Nasdaq: CRDL) is a cardio-renal-metabolic drug developer. Its lead program, CardiolRx (MAVERIC), is in Phase 3 for recurrent pericarditis. Its next catalyst on record is CardiolRx: Cardiol expands Phase III MAVERIC trial enrollment to up to 150 patients and pushes topline results from Q1 2027 to mid-2027. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CardiolRx — Cardiol expands Phase III MAVERIC trial enrollment to up to 150 patients and pushes topline results from Q1 2027 to mid-2027. (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CardiolRx (MAVERIC pivotal trial) | recurrent pericarditis | small molecule | Phase 3 |
| CardiolRx (ARCHER, completed) | acute myocarditis | small molecule | Phase 2 |
| CRD-38 (subcutaneous formulation) | inflammatory heart disease incl. heart failure | small molecule | Pre-clinical |
Recent results and decisions
- Sep 23, 2026completed enrollment Phase III MAVERIC reached its original 110-patient enrollment target ahead of end-of-September guidance; Steering Committee recommends expanding to up to 150 patients after blinded review showed fewer-than-expected recurrences.
As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance.
Filing - Sep 23, 2026positive Blinded review shows fewer-than-expected recurrences of pericarditis in the MAVERIC trial, viewed as encouraging by the Company.
A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx™ or placebo shows a lower level of pericarditis recurrence than anticipated, an observation we view as encouraging.
Filing - Oct 27, 2025positive Previously reported Phase 2 ARCHER topline showed a significant reduction in LV mass in acute myocarditis (no figures given).
Topline results from our ARCHER trial demonstrated a significant reduction in LV mass-marking the first evidence of structural and remodeling improvement in patients with myocarditis.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.